ADXN Stock Overview
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Addex Therapeutics Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 7.90 |
| 52 Week High | CHF 27.90 |
| 52 Week Low | CHF 5.50 |
| Beta | 1.89 |
| 1 Month Change | 4.91% |
| 3 Month Change | -25.47% |
| 1 Year Change | 44.95% |
| 3 Year Change | -94.04% |
| 5 Year Change | n/a |
| Change since IPO | -97.28% |
Recent News & Updates
Recent updates
Addex, Indivior expand team up to develop therapies for substance use disorders
Aug 15Addex stock falls 11% amid $4.2M equity financing with Armistice
Jul 22Addex Therapeutics CEO Tim Dyer - Emerging Drugs For Central Nervous System (Video)
Oct 21Addex, Janssen initiate Phase 2 study of ADX71149 for epilepsy
Jun 07Addex Therapeutics reports Q1 results
May 05Addex drops 23% after pricing share offering
Jan 07Addex Therapeutics files to sell $10M of ADS
Dec 14Addex Therapeutics reports Q3 results
Nov 03Shareholder Returns
| ADXN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.3% | -3.6% | -2.4% |
| 1Y | 45.0% | -2.6% | 23.4% |
Return vs Industry: ADXN exceeded the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: ADXN exceeded the US Market which returned 23.4% over the past year.
Price Volatility
| ADXN volatility | |
|---|---|
| ADXN Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ADXN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ADXN's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 23 | Tim Dyer | www.addextherapeutics.com |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Addex Therapeutics Ltd Fundamentals Summary
| ADXN fundamental statistics | |
|---|---|
| Market cap | US$5.84m |
| Earnings (TTM) | -US$14.19m |
| Revenue (TTM) | US$663.34k |
8.8x
P/S Ratio-0.4x
P/E RatioIs ADXN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADXN income statement (TTM) | |
|---|---|
| Revenue | CHF 592.36k |
| Cost of Revenue | CHF 6.69m |
| Gross Profit | -CHF 6.09m |
| Other Expenses | CHF 6.58m |
| Earnings | -CHF 12.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 24, 2025
| Earnings per share (EPS) | -0.13 |
| Gross Margin | -1,028.84% |
| Net Profit Margin | -2,139.51% |
| Debt/Equity Ratio | 0% |
How did ADXN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 20:17 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Addex Therapeutics Ltd is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Bob Pooler | Bank am Bellevue |
| Silvia Schanz | Bank Vontobel AG |